Uncategorized
Permanent J Code Issued for Avedro’s Photrexa® Drug Formulations
WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., a leading commercial-stage ophthalmic medical technology company and a global leader in corneal remodeling, today announced that the Centers for Medicare and Medicaid Services (CMS) issued a product-specific J code, J2787, for Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution). These Photrexa formulations are the only drugs approved by the U.S. Food and Drug Adm